Form 4: EWTX officer reports 100,000 option exercise; holds 23,400

Rhea-AI Filing Summary

Edgewise Therapeutics (EWTX) filed a Form 4 showing insider activity. On 11/12/2025, a Director and Chief Scientific Officer exercised stock options and sold shares the same day. The insider exercised 100,000 options at an exercise price of $0.18 (code M) and sold 100,000 shares of common stock at an average price of $21.1245 (code S), with trades executed between $21.00 and $21.35.

Following these transactions, the insider directly beneficially owned 23,400 common shares. In addition, 1,147,365 derivative securities (stock options) remained beneficially owned. The exercised option referenced had become exercisable on 06/27/2021 and carries an expiration date of 06/27/2032.

Insider Trade Summary

Exercise and Sale: 100,000 shares ($2.09M approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Russell Alan J

Role Chief Scientific Officer

Sold 100,000 shs ($2.11M)

Approx. gross sale proceeds $2.11M

Approx. exercise cost $18K

Approx. pre-tax spread $2.09M

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	100,000	$0.00	$0.00
Exercise	Common Stock	100,000	$0.18	$18K
Sale	Common Stock	100,000	$21.1245	$2.11M

Holdings After Transaction: Stock Option (Right to Buy) — 1,147,365 shares (Direct); Common Stock — 23,400 shares (Direct)

Footnotes (1)

1. F1. The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $21.00 to $21.35, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 11/13/2025 - 06:06 PM Learn about SEC filing dates

FAQ

What insider transaction did EWTX report on Form 4?

The Director and Chief Scientific Officer exercised 100,000 stock options at $0.18 and sold 100,000 common shares at a $21.1245 average on 11/12/2025.

What was the sale price range for the EWTX shares?

Sales occurred at prices ranging from $21.00 to $21.35, with a $21.1245 average.

How many EWTX shares does the insider own after the transaction?

The insider directly beneficially owned 23,400 common shares following the reported transactions.

How many derivative securities (options) does the insider still hold?

The insider beneficially owned 1,147,365 derivative securities (stock options) after the transactions.

What are the key dates for the exercised option?

The option became exercisable on 06/27/2021 and expires on 06/27/2032.

What roles does the reporting person hold at Edgewise Therapeutics (EWTX)?

The reporting person is a Director and an Officer, serving as Chief Scientific Officer.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Russell Alan J

(Last) (First) (Middle)

C/O EDGEWISE THERAPEUTICS, INC.

1715 38TH STREET

(Street)

BOULDER CO 80301

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Edgewise Therapeutics, Inc. [ EWTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/12/2025		M		100,000	A	$0.18	123,400	D
Common Stock	11/12/2025		S		100,000	D	$21.1245(1)	23,400	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$0.18	11/12/2025		M			100,000	06/27/2021	06/27/2032	Common Stock	100,000	$0.00	1,147,365	D

Explanation of Responses:

1. The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $21.00 to $21.35, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

	/s/ John R. Moore, Attorney-in-Fact for Russell Alan J	11/13/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.